Therapix Biosciences Ltd. (NASDAQ:TRPX) reported H117 results and provided a company update in which it announced that the planned development program for sublingual ultra-low dose THC (THX-ULD01) will focus on the treatment of traumatic brain injury (TBI). The program is planned to enter a Phase I pharmacokinetic study in Q417, expected to take one month to complete. The company also reported that the Phase IIa Tourette’s study of THX-TS01 was going smoothly and eight (of 18) patients have completed the trial, seven of whom opted to remain on the drug.
TBI is a major unmet medical need
TBI is one of the most common medical conditions affecting western countries. In the US there are approximately 2.5m emergency room visits per year from TBI, 300,000 of which result in a hospital in-stay. There is significant need for agents to improve cognitive impairment following TBI, as approximately 37% of patients admitted to the hospital have long-term cognitive disability following the event.
To read the entire report Please click on the pdf File Below: